PAVmed (NASDAQ:PAVM) Stock Rating Reaffirmed by Maxim Group

Share on StockTwits

PAVmed (NASDAQ:PAVM)‘s stock had its “buy” rating restated by investment analysts at Maxim Group in a research report issued on Friday, AnalystRatings.com reports. They presently have a $5.00 price target on the stock. Maxim Group’s price objective would suggest a potential upside of 113.68% from the company’s previous close.

Separately, ValuEngine raised PAVmed from a “sell” rating to a “hold” rating in a research note on Tuesday, March 3rd.

PAVM opened at $2.34 on Friday. The stock has a market capitalization of $118.19 million, a price-to-earnings ratio of -4.25 and a beta of 0.01. PAVmed has a fifty-two week low of $0.81 and a fifty-two week high of $3.45. The company has a fifty day moving average of $2.22 and a 200 day moving average of $1.65.

PAVmed (NASDAQ:PAVM) last issued its quarterly earnings data on Thursday, April 9th. The company reported ($0.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.08).

A number of hedge funds have recently added to or reduced their stakes in PAVM. Virtu Financial LLC purchased a new position in shares of PAVmed in the 4th quarter worth $25,000. M&R Capital Management Inc. bought a new position in shares of PAVmed in the 1st quarter valued at about $49,000. Levin Capital Strategies L.P. lifted its holdings in shares of PAVmed by 500.0% in the 4th quarter. Levin Capital Strategies L.P. now owns 60,000 shares of the company’s stock valued at $72,000 after acquiring an additional 50,000 shares during the last quarter. Buckingham Asset Management LLC purchased a new position in PAVmed in the first quarter worth about $79,000. Finally, Synovus Financial Corp bought a new stake in PAVmed during the first quarter worth approximately $79,000. Institutional investors and hedge funds own 5.88% of the company’s stock.

About PAVmed

PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube.

Featured Article: How to Track your Portfolio in Google Finance

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Usio’s  Buy Rating Reaffirmed at LADENBURG THALM/SH SH
Usio’s Buy Rating Reaffirmed at LADENBURG THALM/SH SH
Navidea Biopharmaceuticals’  “Buy” Rating Reiterated at Maxim Group
Navidea Biopharmaceuticals’ “Buy” Rating Reiterated at Maxim Group
PAVmed  Stock Rating Reaffirmed by Maxim Group
PAVmed Stock Rating Reaffirmed by Maxim Group
Williams-Sonoma  Upgraded to B- by TheStreet
Williams-Sonoma Upgraded to B- by TheStreet
Ross Stores  Stock Rating Lowered by TheStreet
Ross Stores Stock Rating Lowered by TheStreet
Neutral Press Coverage Somewhat Likely to Impact Morgan Stanley  Share Price
Neutral Press Coverage Somewhat Likely to Impact Morgan Stanley Share Price


© 2006-2020 Ticker Report